Pasithea Reports Substantial Tumor Shrinkage With PAS-004 in Early NF1 Study, FDA Clears Phase 2
Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.
Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.
New FDA clearance lets Tandem Mobi users go tubeless for up to 7 days while keeping Control-IQ+ technology. Launch expected in early 2027.
Final European Commission decision pending.
Moderna guided for 15–25% revenue growth in 2026 and said cash costs will rise to approximately $4 billion in 2027, remaining elevated through 2030.
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
Phase 2 FREEDOM2 results for PGN-EDODM1 deliver 46.5% mean splicing correction, functional improvements, and strong analyst support.